Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study

2022307 citationsJournal Articlegold Open Access

Authors

The study was sponsored by AstraZeneca.

Partnerships for the goals

Published in: The Lancet Regional Health - Europe

Volume 20, pp. 100438-100438

Field-Weighted Citation Impact: 42.22